Interview with Maurizio De Cicco, General Manager, Roche Italy
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
Address: Via G.B. Stucchi 110, IT-20052 Monza (Milano),Italy
Tel: +39-039-2471
Web: http://www.roche.it/portal/roche-italia/home
Roche has been present in Italy since 1897, the subsidiary now employs about 1900 over the country. Its turnover in 2007 was over 928 million euros in the pharmaceutical market and 387 million euros in the diagnostic. Its plant is located in Segrate, about 10km from Milan, currently has about 400 employees and can cover all areas from production to packaging.Currently Roche clinical research in Italy takes part in about thirty experimental projects related to different therapeutic areas and involving over 30 researchers Roche and multiple partners among centers and universities and hospitals distributed throughout the country.
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
Writing in the June 2025 edition of DIA’s Global Forum Magazine, Finn McCartney, Maria Dutarte, Petra Adámková, and Paola Kruger from the European Patients’ Academy on Therapeutic Innovation (EUPATI) weigh…
Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the…
A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC…
Some of the biggest pharma and healthcare stories coming out of Italy, including Italy’s antitrust investigation of Novartis and Genentech; Johnson & Johnson’s EUR 125 million investment in its Italian…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
See our Cookie Privacy Policy Here
